Comparing Insulin Degludec And Insulin Glargine

Insulin degludec (Tresiba), a new ultra-long-acting insulin, has a similar or reduced risk of recurrent hypoglycemia - low blood sugar - compared with the commercially available insulin glargine, a new meta-analysis study finds. Results of the combined analysis, of five completed clinical trials, were presented at The Endocrine Society's 95th Annual Meeting in San Francisco. The studies included nearly 3,400 adults with type 2 diabetes who had a daily injection of either insulin degludec or glargine combined with either a mealtime insulin or oral diabetic medications...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Diabetes Source Type: news